RAPP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Rapport Therapeutics Inc (RAPP) is not a strong buy at the moment for a beginner investor with a long-term focus. The lack of significant positive catalysts, weak financial performance, and neutral trading sentiment suggest holding off on investing right now. The stock may not align with the user's impatience and unwillingness to wait for optimal entry points.
The MACD is below 0 and negatively contracting, RSI is neutral at 61.702, and moving averages are converging. The stock is trading near its resistance level of 29.984, with a pivot at 28.185. No clear bullish or bearish signals are present.
Analyst coverage initiated by Wells Fargo with an Overweight rating and a $43 price target, citing best-in-category efficacy potential in focal onset seizures.
No recent news, no significant hedge fund or insider trading activity, and no recent congress trading data. Financial performance remains weak with negative net income and EPS.
In Q4 2025, the company reported no revenue growth (0% YoY), a net income loss of -33.76M (up 68.98% YoY), and an EPS of -0.72 (up 26.32% YoY). Gross margin remains at 0%.
Wells Fargo initiated coverage with an Overweight rating and a $43 price target, citing confidence in the company's Phase 2a data for focal onset seizures.
